Kymera Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)·WATERTOWN, MA·FY end 12/31·CIK 1815442

CEO Pay Ratio

21:1

CEO Total Comp

—

Median Employee

$409,607

Revenue

$39.2M

FY 2025

Net Income

-$311.4M

FY 2025

Free Cash Flow

-$234.3M

FY 2025

Net Margin

-794.0%

Insider Net (180d)

-$70.7M

0 buys / 142 sales

CEO Pay Accountability

CEO comp as % of net income

—

Not enough data to compute.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$39.2M	$47.1M	$78.6M	$46.8M	$72.8M
Gross Profit	—	—	—	—	—	—
Operating Income	-$349.4M	-$261.6M	-$165.5M	-$161.3M	-$100.5M
Net Income	-$311.4M	-$223.9M	-$147.0M	-$154.8M	-$100.2M
Operating CF	-$232.9M	-$194.5M	-$102.8M	-$153.1M	-$128.9M
Capex	$1.4M	$12.8M	$34.5M	$2.8M	$1.6M
Free Cash Flow	-$234.3M	-$207.3M	-$137.3M	-$155.9M	-$130.5M
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	-891.1%	-555.8%	-210.6%	-344.4%	-138.0%
Net Margin	-794.0%	-475.6%	-187.0%	-330.6%	-137.6%
FCF Margin	-597.6%	-440.5%	-174.7%	-333.0%	-179.2%
R&D / Revenue	807.3%	510.4%	240.6%	350.8%	188.1%
Effective Tax	0.0%	—	—	—	—	—
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Nello MainolfiPh.D.	$693.0K	—	$7.3M	$519.8K	$14.0K	$8.5M
Brian AdamsJ.D.	$145.2K	$2.3M	$3.6M	$90.6K	$6.3K	$6.1M
Noah GoodmanMBA	$294.0K	$1.1M	$1.6M	$181.7K	$12.8K	$3.2M
Jared GollobM.D.	$507.1K	$905.1K	$1.2M	$285.2K	$14.0K	$2.9M
Bruce JacobsCFA, MBA	$500.0K	$905.1K	$1.2M	$281.3K	$14.0K	$2.9M